Receipt date: 07/15/2005

Sheet 1

Examine Signature

## JC20 Rec'd PCT/PTO 1

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control num Complete if Known Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary) of 2

/Zachary Howard/

Application Number Based on:PGT/dP200#/060248 Filing Date Intil Fijing 15 JANUARY 2004 First Named Inventor Yasuaki ITO Art Unit tba Examiner Name tba Attorney Docket Number 3136 US0P

				DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (F Insura)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
	A1	<sup>US-</sup> 6,448,005 B1	09/10/2002	M. A. Glucksmann, et al.	
	A2	<sup>US-</sup> 6,395,877 B1	05/28/2002	M. A. Glucksmann, et al.	
	А3	US- 2002/0151705 A1	10/17/2002	K.E. Smith, et al.	
		US-			
		US-	· · · · ·		
		US-			
		US-			
		US-			
	1	US-	-		

Examiner Initiels*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passeges Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>5</sup> 'Number <sup>4</sup> 'Kind Code <sup>5</sup> (if known)				
	A4	JP 2001211885 - Abstract only	08/07/2001	Kyowa Hakko Kogyo Co.		
	A5	WO 02/088182 A1- Abstract only	11/07/2002	Takeda Chemical Industries		
	A6	WO 03/068959 A2-Abstract only	08/21/2003	Takeda Chemical Industries		П
	A7	WO 02/067868 A2	09/06/2002	Millennium Pharmaceuticals		
	A8	WO 00/71584 A2	11/30/2000	Human Genome Sciences		
	A9	WO 01/42288 A2	06/14/2001	Incyte Genomics, Inc.		

02/18/2010 "EXAMINER: Initial if reference considered, whether or not obtation is in conformance with MPEP 650. Dava in lattrough citizolin find in conformance and not considered, include copy of this form with next communication to applicant." Applicant's unique obtation designation number (optional). See Kinds Cobes of USPTO Patent Oscillation, which is usually the documents at www.usedio.ogc or MPEP 8010.4. "Eiter Office but issued the document, by the two-lefter code (WPIO Standard ST.3)." For applications of the year of the reging of the Emperor must precode the serial number of the patent document. "Kind of document by the appropriate symbols as indicated on the document under WPO Standard ST in for possible." Applicant is to piece a other water knew for English indiquage. Translation is attached.

Implications in adult-risk.

Implications of information is required by 3T CFR 187 and 188. The information is required to obtain or retain a bronfit by the public writer is to lise poor by interest to the control of information in the control of incomment of of

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Considered

Examiner Signature

/Zachary Howard/

Approved for use through 07/31/2006. OMB 0651-0031

Substitute for form 14		Co.	THE 1542408
		Application Number	Based on PCT/JP2004/000248
INFORMA	TION DISCLOSURE	Filing Date	Intl. Filing 15 JANUARY 2004
		First Named Inventor	Yasuaki ITO
		Fiting Date Intl. Filing 15 JANUARY 20 First Named Inventor Yasuaki ITO	tba
(Use as	many sheets as necessary)	Examiner Name	tba
Sheet  2	of 2	Attorney Docket Number	3136 USOP

			U. S. PATENT I		
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (f Incom)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			Тідагатфран
	_				
		US-			i
		US-	1		
	_	US-	1		
		US-	1		
		US-			
		US-	1		
		US-			
		US-			
	T	US-	1		
		US-			
		US-			
		US-	1		
		US-			
		US-	1		
	_	US-	1		

		FORE	IGN PATENT DOCL	IMENTS		
Exeminer Initials*	Cite No.1	Foreign Petent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Peges, Columns, Lines, Where Relevant Passages Or Relevent Figures Appear	Г
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>3</sup> (if known)				T <sup>6</sup>
	A10	WO 01/57188 A2	08/09/2001	Hyseq, Inc.		
	A11	WO 01/62797 A2	08/30/2001	Pharmacia & Upjohn		Г
	A12	WO 02/061087 A2	08/08/2002	Lifespan Biosciences, Inc.		Г
	A13	WO 01/77330 A2	10/18/2001	Pharmacia & Upjohn		
	A14	WO 02/42461 A2	05/30/2002	Arena Pharmaceuticals, Inc.		
	A15	WO 02/068600 A2	09/06/2002	Arena Pharmaceuticals, Inc.		Г

\*EXAMINER: Initial if reference considered, whether or not classion is in conformance with MPEP 689. Dava line through classion if not in conformance and not considered, include copy of this form with next communication to applicant, "Applicant's unique citation designation number (optional)," See Kinds Codes of USPTO Patent Downments at www. upglobage or MPEP 9010.4. "Extent Office this issued the document, by the two-letter code (WIPPO Standed's ST.3)," For Japanese patent document, is the indication of the year of the regno of the Emperor must precade the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPPO Standed's ST.4 if possible. "Applicant is to place a check mark here it English inequage Translation is attached.

Impressions attractions in required by 27 CFR 137 and 198. The information is required to potent or retain a broad by the public which is to fits (and by the USPTO) processor, and applications. Confidentially is governed by \$8 U.S.C. 122 and \$3 CFR 1.14. This collection is estimated to take 2 heaves to compute, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggesterors for methicing this burdon, should be sent to the Chief Information Officer, U.S. Patient and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Considered